发明授权
US5215894A Biological process for producing 17.beta.-N-monosubstituted
carbamoyl-11-oxo-4-aza-5-.alpha.-androst-3-one testosterone-5-.alpha.
reductase inhibitors
失效
用于生产17β-单取代氨基甲酰基-11-氧代-4-氮杂-5α-雄甾-3-酮睾酮-5-α还原酶抑制剂的生物学方法
- 专利标题： Biological process for producing 17.beta.-N-monosubstituted carbamoyl-11-oxo-4-aza-5-.alpha.-androst-3-one testosterone-5-.alpha. reductase inhibitors
- 专利标题（中）： 用于生产17β-单取代氨基甲酰基-11-氧代-4-氮杂-5α-雄甾-3-酮睾酮-5-α还原酶抑制剂的生物学方法
-
申请号： US841923申请日： 1992-02-25
-
公开(公告)号： US5215894A公开(公告)日： 1993-06-01
- 发明人: Byron H. Arison , Josephine R. Carlin , Edamanal S. Venkataramani
- 申请人： Byron H. Arison , Josephine R. Carlin , Edamanal S. Venkataramani
- 申请人地址： NJ Rahway
- 专利权人： Merck & Co., Inc.
- 当前专利权人： Merck & Co., Inc.
- 当前专利权人地址： NJ Rahway
- 主分类号： C12P33/10
- IPC分类号： C12P33/10
摘要：
The present invention is concerned with a novel biotransformation process for producing 17.beta.-N-monosubstituted carbamoyl-11-oxo-4-aza-5-.alpha.-androst-3-ones of the formula: ##STR1## These compounds are testosterone 5-.alpha. reductase inhibitors and are produced via a claimed novel biotransformation process using the green algae, Selenastrum capricornutum.